SENSEX NIFTY
YOU ARE HERE >  Moneycontrol Markets > Announcements PharmaceuticalsAnnouncement - Glenmark
Glenmark
BSE: 532296NSE: GLENMARKISIN: INE935A01035

26th-Jul-2011 09:06Source: BSE

Glenmark - Glenmark Pharmaceuticals Limited has received USD 15 million from Salix Pharmaceuticals, Inc, USA

Glenmark Pharmaceuticals Ltd has informed BSE that the Company has received USD 15 million from Salix Pharmaceuticals, Inc, USA. This is as per an Agreement for Advance against Commitment fee which is to cover Glenmark's risks associated with upgrading its manufacturing facilities to meet Salix's anticipated increased requirements in demand for Crofelemer.

Through an agreement between the two companies, Salix agreed to pay Glenmark a $ 21.6 million commitment fee in five equal annual installments, with the first annual installment in July 2012, in view of Glenmark's investment in, and risks associated with, upgrading its manufacturing facilities to increase the production capacity of crofelemer. The commitment fee is in addition to the compound purchase price payable by Salix to Glenmark.

After remitting the advance of USD 15 million to Glenmaric, Salix will pay Glenmark the remaining $ 6.6 million of the conimitment fee in five equal annual installments.

OUR WINNING PICKS

DID YOU INVEST?

INTRADAY PICKS!

(September 29, 2014)

AT (Rs)



GAIN (Rs)

ALL TIME WINNERS

RECO PRICE

PEAK PRICE

OUR PACKAGES

Super Combo
3150

Powerful mix of both trader and investor packs with timely expert advice.

Technical
1890

Designed especially for traders looking to tap the profit opportunities of volatile markets.

Fundamental
1890

For all investors looking to unearth stocks that are poised to move.

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.